WO2011113005A3 - Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo) - Google Patents

Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo) Download PDF

Info

Publication number
WO2011113005A3
WO2011113005A3 PCT/US2011/028206 US2011028206W WO2011113005A3 WO 2011113005 A3 WO2011113005 A3 WO 2011113005A3 US 2011028206 W US2011028206 W US 2011028206W WO 2011113005 A3 WO2011113005 A3 WO 2011113005A3
Authority
WO
WIPO (PCT)
Prior art keywords
combinations
methods
oligoamines
dfmo
difluoromethylornithine
Prior art date
Application number
PCT/US2011/028206
Other languages
French (fr)
Other versions
WO2011113005A2 (en
WO2011113005A8 (en
Inventor
Robert A. Casero
Laurence J. Marton
Original Assignee
The Johns Hopkins University
Progen Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University, Progen Pharmaceuticals filed Critical The Johns Hopkins University
Priority to US13/634,237 priority Critical patent/US20130197088A1/en
Publication of WO2011113005A2 publication Critical patent/WO2011113005A2/en
Publication of WO2011113005A3 publication Critical patent/WO2011113005A3/en
Publication of WO2011113005A8 publication Critical patent/WO2011113005A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is based on the seminal discovery of a synergistic effect for combinations of oligoamines with 2-difluorornethylornithine (DFMO) for treatment of cancer. The invention provides combinations of at least one inhibitor of a histone demethylase enzyme and at least one inhibitor of ornithine decarboxylase (ODC). The invention also provides methods for treatment of cancer using such combinations and methods for altering methylation in a cell using such combinations. The invention provides that certain silenced genes can be re-expressed using combinations disclosed herein.
PCT/US2011/028206 2010-03-12 2011-03-11 Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo) WO2011113005A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/634,237 US20130197088A1 (en) 2010-03-12 2011-03-11 Compositions and Methods for Combinations of Oligoamines with 2-Difluoromethylornithine (DFMO)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31331310P 2010-03-12 2010-03-12
US61/313,313 2010-03-12

Publications (3)

Publication Number Publication Date
WO2011113005A2 WO2011113005A2 (en) 2011-09-15
WO2011113005A3 true WO2011113005A3 (en) 2012-01-19
WO2011113005A8 WO2011113005A8 (en) 2012-10-26

Family

ID=44564164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/028206 WO2011113005A2 (en) 2010-03-12 2011-03-11 Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo)

Country Status (2)

Country Link
US (1) US20130197088A1 (en)
WO (1) WO2011113005A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
US9487512B2 (en) 2011-10-20 2016-11-08 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2361242B1 (en) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidase inhibitors and their use
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
EP3133059A1 (en) 2010-04-19 2017-02-22 Oryzon Genomics, S.A. Lysine specific demethylase-1 inhibitors and their use
CN103124724B (en) 2010-07-29 2015-05-20 奥瑞泽恩基因组学股份有限公司 Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
WO2012107499A1 (en) * 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
EA201892075A1 (en) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. COMBINATION OF LSD1 INHIBITORS FOR USE FOR THE TREATMENT OF SOLID TUMORS
KR102511028B1 (en) 2016-03-15 2023-03-16 오리존 지노믹스 에스.에이. Combinations of LSD1 inhibitors for the treatment of hematological malignancies
US20170273926A1 (en) 2016-03-24 2017-09-28 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
SG11201710199PA (en) 2016-06-10 2018-05-30 Oryzon Genomics Sa Methods of treating multiple sclerosis
SG11201811755PA (en) * 2016-07-01 2019-01-30 Agency Science Tech & Res A wound healing composition
EP3551178A1 (en) 2016-12-09 2019-10-16 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors
EP4384187A1 (en) * 2021-08-11 2024-06-19 Cambridge Enterprise Limited Use of polyamines in the treatment of brain tumours

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002091989A2 (en) * 2000-11-08 2002-11-21 Slil Biomedical Corporation Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
US20030083384A1 (en) * 2001-08-29 2003-05-01 Bristol-Myers Squibb Company To Women First Healthcare, Inc. Processes for the production of alpha-difluoromethyl ornithine (DFMO)
WO2006041805A1 (en) * 2004-10-04 2006-04-20 Cellgate, Inc. Polyamine analogs as therapeutic agents for ocular diseases
WO2007021839A2 (en) * 2005-08-10 2007-02-22 Johns Hopkins University Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002091989A2 (en) * 2000-11-08 2002-11-21 Slil Biomedical Corporation Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
US20030083384A1 (en) * 2001-08-29 2003-05-01 Bristol-Myers Squibb Company To Women First Healthcare, Inc. Processes for the production of alpha-difluoromethyl ornithine (DFMO)
WO2006041805A1 (en) * 2004-10-04 2006-04-20 Cellgate, Inc. Polyamine analogs as therapeutic agents for ocular diseases
WO2007021839A2 (en) * 2005-08-10 2007-02-22 Johns Hopkins University Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
US9487512B2 (en) 2011-10-20 2016-11-08 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors

Also Published As

Publication number Publication date
WO2011113005A2 (en) 2011-09-15
WO2011113005A8 (en) 2012-10-26
US20130197088A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
WO2011113005A8 (en) Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo)
EP3489360A3 (en) Modulation of nuclear-retained rna
MX343559B (en) Modulation of transthyretin expression.
EP2588729A4 (en) Low emission triple-cycle power generation systems and methods
EP2588732A4 (en) Low emission triple-cycle power generation systems and methods
WO2010132882A3 (en) Sublingual dexmedetomidine compositions and methods of use thereof
EA201101053A1 (en) PHOSPHYNOSIS INHIBITORS ITID-3-KINAZ WITH ZINC-BINDING GROUP
WO2013059582A3 (en) Small molecule inhibitors of histone deacteylases
WO2010033920A3 (en) Compositions and methods for enhancing cell reprogramming
WO2011153234A3 (en) Methods of inhibiting alu rna and therapeutic uses thereof
MX2013005673A (en) Nk cell modulating treatments and methods for treatment of hematological malignancies.
WO2010141417A3 (en) Systems and methods for impairing smooth muscle tissue function
MX2014013446A (en) Ketol-acid reductoisomerase enzymes and methods of use.
WO2012158624A3 (en) Inhibitors of mitochondrial fission and methods of use thereof
IL225442A0 (en) Compositions comprising rankl inhibitors for use in treating and preventing cancer
BR112014027488A2 (en) vegetable isoprene synthase for isoprene production
MX2009013982A (en) Compositions comprising tryptophan hydroxylase inhibitors.
GB201302383D0 (en) Processor power management based on class and content instructions
WO2014143855A3 (en) Combination cancer treatments utilizing micrornas and egfr-tki inhibitors
EA200970284A1 (en) INHIBITORS OF HYSTON DEZACETILAS WITH COMBINED ACTIVITY WITH RESPECT TO HYSTONE DEZACETYLASES OF CLASS I AND CLASS II IN COMBINATION WITH THE INHIBITORS PROTEAS
PH12015500069A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
WO2012088130A3 (en) Low-memory-usage arbitrary waveform representation of generation
WO2011150457A3 (en) Haematopoietic-prostaglandin d2 synthase inhibitors
WO2011143344A3 (en) Use of brown midrib-3 gene specific markers in maize for trait introgression
WO2012018597A9 (en) Compositions and methods for enhancing the effectiveness of systemic, hipec, ip, and related cancer treatments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11754215

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13634237

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 11754215

Country of ref document: EP

Kind code of ref document: A2